Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
4.610
+0.200 (4.54%)
At close: Feb 6, 2026, 4:00 PM EST
4.490
-0.120 (-2.60%)
After-hours: Feb 6, 2026, 7:55 PM EST
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.26 billion as of February 6, 2026. Its market cap has increased by 302.72% in one year.
Market Cap
1.26B
Enterprise Value
1.03B
1-Year Change
302.72%
Ranking
Category
Stock Price
$4.61
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.26B, an increase of 82.90%. That is a compound annual growth rate of 11.89%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 6, 2026 | 1.26B | -16.18% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Intellia Therapeutics | 1.28B |
| Novavax | 1.28B |
| Fortrea Holdings | 1.28B |
| Savara | 1.27B |
| AtaiBeckley | 1.24B |
| Rapport Therapeutics | 1.22B |
| Capricor Therapeutics | 1.19B |
| Inhibrx Biosciences | 1.19B |